Puma Biotechnology, Inc. (NASDAQ: PBYI) is a Healthcare company (Biotechnology) with a market capitalization of $362M. The Maz Rating grades it against the other companies in its sector.
Puma Biotechnology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $7.01, Puma Biotechnology, Inc. trades at 15.4x trailing earnings, 1.6x sales and 2.6x book value, with an EV/EBITDA of 8.5. Over the last twelve months it generated about $221M of revenue and $24M of net income. It runs a gross margin of 73.6%, an operating margin of 11.3% and a net margin of 10.3%. It shows return on equity of 17.5%, return on invested capital of 14.6% and a free cash flow yield of 12.1%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 3.03. Over the past 52 weeks the share price ranged from $3.03 to $11.50, with a beta of 1.21.
Puma Biotechnology, Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 8 Buy, 8 Hold and 4 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Puma Biotechnology, Inc. (PBYI) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 22.2% / 30% · Interest income / Revenue 1.60% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 22.2% / 33% · Receivables / Mkt Cap (36m) 6.72% / 49% · Interest income / Revenue 1.60% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 22.2% / 33.33% · Receivables / Mkt Cap (24m) 6.72% / 33.33% · Interest income / Revenue 1.60% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 4.20% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 49.9% / 33.33% · Receivables / Avg Assets (4Q) 18.3% / 33.33% · Interest income / Revenue 1.60% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 53.5% / 33.33% · (Cash+Recv) / Total Assets 69.7% / 33.33% · Interest income / Revenue 1.60% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Puma Biotechnology, Inc. (PBYI) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Puma Biotechnology, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.60% of each dividend: Puma Biotechnology, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.